Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

急性肺损伤（ALI）及其更严重的形式，成人呼吸窘迫（ARD），是一种毁灭性的临床综合征的突然肺部炎症，导致严重水肿和低氧血症，需要在重症监护室护理。在受控环境中，死亡率在30-40%之间。迄今为止，尽管有许多大型和小型的临床试验，但没有单一药物被证明能有效改善ALI/ARDS的死亡率。临床研究网络（ARDSNet）的目标是开发和进行临床研究试验，以预防，治疗和改善急性肺损伤，急性呼吸窘迫综合征和其他相关危重疾病患者的结局。 每年至少入组30例ALI/ARDS患者。详细描述患者人群的性别和种族特征。 确定方案制定的优先事项并参与方案制定，制定具体方案，确定受试者资格标准，制定数据电子传输程序，制定知情同意书样本。 作为SC的投票成员;参加会议和电话会议。 参加一个或多个小组委员会（例如，出版物、伦理学、病理学、自然史和进展评估），将根据需要举行会议和电话会议。可能要求研究者参加方案审查委员会（PRC）和数据与安全性监查委员会（DSMB）会议和电话会议，作为资源。

Acute lung injury (ALI) and its more severe form, adult respiratory distress (ARD), is a devastating clinical syndrome of sudden lung inflammation that results in severe edema and hypoxemia and requires care in the intensive care unit. Mortality is between 30-40% in controlled settings. To date, no single drug has proven effective for improving mortality in ALI/ARDS despite many large and small clinical trials. The objective of the Clinical Research Network (ARDSNet) is to develop and conduct clinical research trials to prevent, treat, and improve the outcome of patients with acute lung injury, acute respiratory distress syndrome, and possibly other related critical illnesses. Enroll a minimum of 30 patients per year with ALI/ARDS. Describe in detail the gender and racial characteristics of the patient population. Set priorities for and participate in protocol development, developing specific protocols, determination of subject eligibility criteria, developing procedures for electronic transmission of data, developing sample consent forms. Be voting members of the SC; attend meetings and teleconferences. Participate in one or more of a number of subcommittees (e.g., publications, ethics, pathology, natural history, and progress assessment) which will hold meetings and teleconferences on an as-needed basis. Investigators may be asked to participate in Protocol Review Committee (PRC) and Data and Safety Monitoring Board (DSMB) meetings and teleconferences to serve as a resource.